Cargando…

Cancer prevention and screening: the next step in the era of precision medicine

A primary mode of cancer prevention and early detection in the United States is the widespread practice of screening. Although many strategies for early detection and prevention are available, adverse outcomes, such as overdiagnosis and overtreatment, are prevalent among those utilizing these approa...

Descripción completa

Detalles Bibliográficos
Autores principales: Loomans-Kropp, Holli A., Umar, Asad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349901/
https://www.ncbi.nlm.nih.gov/pubmed/30701196
http://dx.doi.org/10.1038/s41698-018-0075-9
_version_ 1783390344865382400
author Loomans-Kropp, Holli A.
Umar, Asad
author_facet Loomans-Kropp, Holli A.
Umar, Asad
author_sort Loomans-Kropp, Holli A.
collection PubMed
description A primary mode of cancer prevention and early detection in the United States is the widespread practice of screening. Although many strategies for early detection and prevention are available, adverse outcomes, such as overdiagnosis and overtreatment, are prevalent among those utilizing these approaches. Broad use of mammography and prostate cancer screening are key examples illustrating the potential harms stemming from the detection of indolent lesions and the subsequent overtreatment. Furthermore, there are several cancers for which prevention strategies do not currently exist. Clinical and experimental evidence have expanded our understanding of cancer initiation and progression, and have instructed the development of improved, precise modes of cancer prevention and early detection. Recent cancer prevention and early detection innovations have begun moving towards the integration of molecular knowledge and risk stratification profiles to allow for a more accurate representation of at-risk individuals. The future of cancer prevention and early detection efforts should emphasize the incorporation of precision cancer prevention integration where screening and cancer prevention regimens can be matched to one’s risk of cancer due to known genomic and environmental factors.
format Online
Article
Text
id pubmed-6349901
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-63499012019-01-30 Cancer prevention and screening: the next step in the era of precision medicine Loomans-Kropp, Holli A. Umar, Asad NPJ Precis Oncol Perspective A primary mode of cancer prevention and early detection in the United States is the widespread practice of screening. Although many strategies for early detection and prevention are available, adverse outcomes, such as overdiagnosis and overtreatment, are prevalent among those utilizing these approaches. Broad use of mammography and prostate cancer screening are key examples illustrating the potential harms stemming from the detection of indolent lesions and the subsequent overtreatment. Furthermore, there are several cancers for which prevention strategies do not currently exist. Clinical and experimental evidence have expanded our understanding of cancer initiation and progression, and have instructed the development of improved, precise modes of cancer prevention and early detection. Recent cancer prevention and early detection innovations have begun moving towards the integration of molecular knowledge and risk stratification profiles to allow for a more accurate representation of at-risk individuals. The future of cancer prevention and early detection efforts should emphasize the incorporation of precision cancer prevention integration where screening and cancer prevention regimens can be matched to one’s risk of cancer due to known genomic and environmental factors. Nature Publishing Group UK 2019-01-28 /pmc/articles/PMC6349901/ /pubmed/30701196 http://dx.doi.org/10.1038/s41698-018-0075-9 Text en © This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Perspective
Loomans-Kropp, Holli A.
Umar, Asad
Cancer prevention and screening: the next step in the era of precision medicine
title Cancer prevention and screening: the next step in the era of precision medicine
title_full Cancer prevention and screening: the next step in the era of precision medicine
title_fullStr Cancer prevention and screening: the next step in the era of precision medicine
title_full_unstemmed Cancer prevention and screening: the next step in the era of precision medicine
title_short Cancer prevention and screening: the next step in the era of precision medicine
title_sort cancer prevention and screening: the next step in the era of precision medicine
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349901/
https://www.ncbi.nlm.nih.gov/pubmed/30701196
http://dx.doi.org/10.1038/s41698-018-0075-9
work_keys_str_mv AT loomanskropphollia cancerpreventionandscreeningthenextstepintheeraofprecisionmedicine
AT umarasad cancerpreventionandscreeningthenextstepintheeraofprecisionmedicine